Материал из Wiki Mininuniver
Перейти к навигацииПерейти к поиску
|
|
| Строка 1: |
Строка 1: |
| − | Non-Hodgkin's lymphoma (NHL), a cancer affecting the lymphatic technique, is the second-fastest-rising cancer in the United States. Incidence rates have practically doubled more [http://www.onetoonecancercenter.com/ cancer treatment center] than the past 30 years. It is estimated that 360,000 Americans are presently living with NHL, and about 58,000 new circumstances are expected to occur in the United States this year.<br><br>NHL is difficult to target and treat, as the disease can be [http://www.onetoonecancercenter.com/ cyberknife radiosurgery] discovered throughout the body in any blood-filtering tissue such as bone marrow. Patients generally have multiple relapses, which means the cancer returns several instances. This tends to make it extremely essential for patients, their caretakers and their loved ones to talk to a physician about all readily available treatment possibilities and to get access to the newest therapies.<br><br>NHL patients are traditionally treated with chemotherapy and/or radiation therapy. Whilst these therapies destroy cancer cells, they also destroy surrounding healthy cells. Furthermore, chemotherapy and radiation therapy can take up to five months to full and could require patients to remain in the hospital.<br><br>An innovative class of drugs is harnessing the immune program to fight NHL. Radioimmunotherapy (RIT) is a promising area of cancer therapy that combines the specificity of monoclonal antibodies (similar to other antibodies the immune method tends to make to fight infection) with the cell-killing potential of radiation. When injected into a patient, these radiation-carrying antibodies seek out and bind to certain tumor cells, and then deliver radiation directly to those and [http://www.onetoonecancercenter.com/ radiation treatment for cancer] surrounding cells.<br><br>Two RIT products have been approved by the U.S. Food and Drug Administration (FDA). These products are completed in just 1 therapy regimen, lasting 1-two weeks, so patients do not want to regularly return to their doctor's office for therapy on a weekly or semiweekly basis. Coupled with the fact that RIT can be administered on an outpatient basis, these therapies provide a lot more convenience for patients and their households. Current studies have shown that NHL patients might benefit most from these therapies when they are utilised early in the therapy of NHL, prior to numerous courses of chemotherapy.<br><br>RIT delivers radiation to B-cells by recognizing and attaching to the CD20 antigen.
| + | Content removed |
Версия 18:05, 18 декабря 2025
